Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Valneva SE
  6. News
  7. Summary
    VLA   FR0004056851

VALNEVA SE

(VLA)
  Report
Real-time Euronext Paris  -  11:35 2022-08-19 am EDT
9.724 EUR   -1.84%
08/18Valneva Starts Rolling Submission Of US FDA Biologics License Application For Chikungunya Vaccine
MT
08/18French Drugmaker Valneva's COVID-19 Jab Gets WHO Recommendation
MT
08/18Valneva Initiates Rolling Submission of US FDA Biologics License Application for Chikungunya Vaccine
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer Completes 8% Stake Purchase in French Vaccine Maker Valneva

06/23/2022 | 11:07pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
PFIZER, INC. 1.17% 49.15 Delayed Quote.-16.77%
VALNEVA SE -1.84% 9.724 Real-time Quote.-60.31%
All news about VALNEVA SE
08/18Valneva Starts Rolling Submission Of US FDA Biologics License Application For Chikungun..
MT
08/18French Drugmaker Valneva's COVID-19 Jab Gets WHO Recommendation
MT
08/18Valneva Initiates Rolling Submission of US FDA Biologics License Application for Chikun..
MT
08/18Valneva Initiates Rolling Submission of FDA Biologics License Application for its Singl..
GL
08/18Valneva Initiates Rolling Submission of FDA Biologics License Application for its Singl..
AQ
08/18Valneva SE Initiates Rolling Submission of U.S. Food and Drug Administration Biologics ..
CI
08/18Valneva's COVID-19 Vaccine Recommended for Use by World Health Organization
MT
08/18WHO recommends Valneva's COVID vaccine
RE
08/18WHO recommends Valneva's COVID vaccine
RE
08/18Valneva Says Pentagon Didn't Exercise 2nd Option Year of Supply Contract for Japanese E..
MT
More news
Analyst Recommendations on VALNEVA SE
More recommendations
Financials
Sales 2022 339 M 341 M 341 M
Net income 2022 -26,4 M -26,5 M -26,5 M
Net cash 2022 220 M 221 M 221 M
P/E ratio 2022 -41,4x
Yield 2022 -
Capitalization 1 140 M 1 144 M 1 144 M
EV / Sales 2022 2,71x
EV / Sales 2023 3,37x
Nbr of Employees 700
Free-Float 68,2%
Chart VALNEVA SE
Duration : Period :
Valneva SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Last Close Price 9,72 €
Average target price 15,82 €
Spread / Average Target 62,7%
EPS Revisions
Managers and Directors
Thomas Lingelbach President & Chief Executive Officer
Franck Charles Marie Grimaud Director General & Chief Business Officer
Peter Buhler Chief Financial Officer
Frédéric Grimaud Chairman-Supervisory Board
Michael Möhlen Vice President-Technical Development
Sector and Competitors
1st jan.Capi. (M$)
VALNEVA SE-60.31%1 144
MODERNA, INC.-40.94%58 680
LONZA GROUP AG-24.63%44 689
IQVIA HOLDINGS INC.-15.28%44 542
SEAGEN INC.11.04%31 186
ALNYLAM PHARMACEUTICALS, INC.31.77%26 820